Key Details
Price
$54.23Last Dividend
$0.33Annual ROE
10.31%Beta
1.23Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Aug 08, 2024Next ex-dividend date:
Dec 04, 2024Recent ex-dividend date:
Sept 11, 2024Next split:
N/ARecent split:
Sept 29, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet to participate in investor conferences in December.
PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet declares regular quarterly dividend.
Examine Avnet's (AVT) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech's proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. This is believed to be the first marketing authorization application filing announced globally for a biosimilar candidate to Simponi. The approvals process is anticipated to be completed in the fourth quarter of 2025.
While the top- and bottom-line numbers for Avnet (AVT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab).
REYKJAVIK, Iceland, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab).
MELBOURNE, Australia--(BUSINESS WIRE)---- $AVT #Avnet--Avnet has been awarded the contract to supply Huizhong's SCL61H-100 smart ultrasonic water meters to South East Water (SEW).
24/7 Wall St. Insights Companies that raise their dividends regularly are outstanding ideas for investors.
PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet names Ginnie Henkels and Helmut Gassel to its Board of Directors.
FAQ
- What is the primary business of Avnet?
- What is the ticker symbol for Avnet?
- Does Avnet pay dividends?
- What sector is Avnet in?
- What industry is Avnet in?
- What country is Avnet based in?
- When did Avnet go public?
- Is Avnet in the S&P 500?
- Is Avnet in the NASDAQ 100?
- Is Avnet in the Dow Jones?
- When was Avnet's last earnings report?
- When does Avnet report earnings?
- Should I buy Avnet stock now?